国庆献礼！艾德生物HRD试剂盒被NMPA纳入创新医疗器械

参考文献

1.Weichert W, Lukashchuk N, Yarunin A, et al.  An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancerInternational Journal of Gynecologic Cancer 2021;31:A366.

2.Yongpai Peng, Qingsheng Xie, Guocai Xu, and Bingzhong Zhang. The correlation of homologous recombination deficiency status with and Olaparib efficacy in Chinese ovarian cancer patients. Journal of Clinical Oncology 2022 40:16_suppl, e17556.

3.Wilko Weichert, et al. 572P High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer. ESMO, 2022.

4.Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, Vacirca D, Colombo N, Barberis M. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica. 2022 Aug;114(4):288-294.

5.Scheiter, A, et al. Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities. J. Pers. Med. 2022, 12, 1270.

6.Yuan W, Ni J, Wen H, Shi W, Chen X, Huang H, Zhang X, Lu X, Zhu C, Dong H, Yang S, Wu X, Chen X. Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability. BJOG. 2022 Nov;129 Suppl 2:14-22.

7.Hillary Stires, et al. Assessing Variability Across HRD Assays: Findings from the Friends’ HRD Harmonization Project. AMP Poster, 2022.

8.Magliacane G, Brunetto E, Calzavara S, et al. Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! Cancers (Basel). 2022 Dec 21;15(1):43.

9.Liu H, Zhang Z, Chen L, Pang J, Wu H, Liang Z. Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma. Front Oncol. 2022 Jan 12;11:798173.

10.Doig KD, Fellowes AP, Fox SB. Homologous Recombination Repair Deficiency: An Overview for Pathologists. Mod Pathol. 2023 Mar;36(3):100049.

11.Dana Ruminski Lowe, er al. Multi-site evaluation of FFPE homologous recombination deficiency reference materials.Cancer Res (2023) 83 (7_Supplement): 6110.

12.Kekeeva T, et al. HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? Int J Mol Sci. 2023 Jun 22;24(13):10497.

13.Feng C, Zhang Y, Wu F, Li J, Liu M, Lv W, Li C, Wang W, Tan Q, Xue X, Ma X, Zhang S. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score. Breast. 2023 Jun;69:392-400.